Silo Pharma, Inc. (SILO): Nasdaq/NYSE listing notice — Silo Pharma receives Nasdaq extension until June 22, 2026 to regain minimum bid price compliance

Silo Pharma, Inc.

Company failed to meet $1.00 minimum bid price requirement by initial Dec. 24, 2025 deadline.
Nasdaq granted a 180-day extension, new compliance deadline is June 22, 2026.
Common stock continues trading on The Nasdaq Capital Market under symbol SILO.
If bid price closes at or above $1.00 for 10 consecutive business days, compliance will be achieved.
Company may consider a reverse stock split during second compliance period if needed.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 27, 2025, the Company received a notification (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company init

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Silo Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-125838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.